<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270659</url>
  </required_header>
  <id_info>
    <org_study_id>1774</org_study_id>
    <nct_id>NCT01270659</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury</brief_title>
  <acronym>FAIRTOP II</acronym>
  <official_title>Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate fentanyl buccal tablet (FBT) for analgesia
      in comparison to standard analgesia, to determine if the FBT allows for faster achievement
      of &quot;significant analgesia&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects/patients will be asked if they would desire a low dose or high dose pain
      medication regimen. The low dose (low-FBT) group will receive FBT at a dose of 100 mcg, as
      well as an oral (pill) placebo preparation. The low dose (low-control) group will receive an
      &quot;inactive comparator&quot; (lansoprazole rapidly-dissolving buccal 15mg, &quot; FBT placebo&quot;) and a
      dose of 5/325 Percocet tablet (oxycodone/acetaminophen 5/325). The high dose (high-FBT)
      group will receive 200 mcg FBT plus 2 placebo tablets. The high dose (high-control) group
      will receive the &quot;FBT placebo&quot; and a dose of 2, 5/325 Percocet tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Level</measure>
    <time_frame>every 5 minutes for 60 minutes</time_frame>
    <description>The study's primary endpoint will be the time at which subjects' pain levels dropped significantly (1.3 units) from the initial pain level, using a verbally administered 10 point pain scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea level</measure>
    <time_frame>every 5 minutes for the first 60 minutes</time_frame>
    <description>Subjects nausea level will be recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>the full 2 hours of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Low-FBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive FBT and placebo at a low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-FBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive the high dose regimen of FBT and a high dose placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl buccal tablet 100 mcg once</description>
    <arm_group_label>Low-FBT</arm_group_label>
    <other_name>Fentora 100 mcg buccal tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl buccal tablet 200 mcg once</description>
    <arm_group_label>High-FBT</arm_group_label>
    <other_name>Fentora buccal tablet 200 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/acetaminophen</intervention_name>
    <description>Oxycodone/acetaminophen 5/325 mg once</description>
    <arm_group_label>Low control</arm_group_label>
    <other_name>Percocet 5/325</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone/acetaminophen</intervention_name>
    <description>Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
    <arm_group_label>High control</arm_group_label>
    <other_name>Percocet 5/325</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pain sufficient to warrant medication stronger than acetaminophen (Tylenol) or
             aspirin

          -  only if Emergency Department provider approves

          -  a negative pregnancy test is required for participation for women of childbearing age

        Exclusion Criteria:

          -  If treating provider determines intravenous analgesia is required

          -  allergy to acetaminophen or any opiate/opioid, or lansoprazole patients currently
             taking phenothiazines, CNS depressants (including alcohol), or if they have taken an
             monoamine oxidase inhibitor (MAOI) or selective serotonin reuptake inhibitor (SSRI)
             in the past two weeks

          -  if patient has already been administered an opioid analgesic for their current injury

          -  patients on chronic opioids therapy or a history of opioid abuse

          -  breastfeeding mothers

          -  patients who plan to drive home after their emergency department visit

          -  history of phenylketonuria (due to phenylalanine in the formulation of the
             lansoprazole solutab)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen H Thomas, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette O Arthur, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillcrest Medical Center Emergency Department</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 2, 2014</lastchanged_date>
  <firstreceived_date>January 4, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fentanyl buccal tablet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
